Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure

Journal of Viral Hepatitis

Volumn 22, Issue 12, 2015, Pages 992-1001

  Ogawa, E ^a   Furusyo, N ^a   Dohmen, K ^b   Kajiwara, E ^c   Kawano, A ^d   Nomura, H ^e   Takahashi, K ^f   Satoh, T ^g   Azuma, K ^h   Nakamuta, M ⁱ   Koyanagi, T ^j   Kotoh, K ^k   Shimoda, S ^k   Hayashi, J ^l  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

^b CHIHAYA HOSPITAL   (Japan)

^c STEEL MEMORIAL YAWATA HOSPITAL   (Japan)

^d KITAKYUSHU MUNICIPAL MEDICAL CENTER   (Japan)

^e Shin Kokura Hospital   (Japan)

^f HAMANOMACHI HOSPITAL   (Japan)

^g Kokura Medical Center   (Japan)

^h Kyushu Central Hospital   (Japan)

ⁱ NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^j Fukuoka City Hospital   (Japan)

^k KYUSHU UNIVERSITY   (Japan)

^l Hara Doi Hospital   (Japan)

more..

Author keywords

hepatitis C virus; pegylated interferon; ribavirin; simeprevir; telaprevir

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; SIMEPREVIR; TELAPREVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; CARRIER PROTEIN; MACROGOL DERIVATIVE; NS3 PROTEIN, HEPATITIS C VIRUS; NS4A COFACTOR PEPTIDE, HEPATITIS C VIRUS; OLIGOPEPTIDE; RECOMBINANT PROTEIN; VIRUS PROTEIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; AMINO ACID SUBSTITUTION; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CHRONIC HEPATITIS C; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENETIC POLYMORPHISM; GLOMERULUS FILTRATION RATE; HEPATITIS C VIRUS SUBTYPE 1B; HUMAN; HUMAN TISSUE; JAPANESE (PEOPLE); KIDNEY FUNCTION; LIMIT OF QUANTITATION; LIVER BIOPSY; LIVER FAILURE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RASH; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE COUNT; TREATMENT FAILURE; TREATMENT RESPONSE; CLASSIFICATION; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG EFFECTS; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; JAPAN; LIVER CIRRHOSIS; MULTICENTER STUDY; PATHOLOGY; RECURRENT DISEASE; VIROLOGY;

AGED; ANTIVIRAL AGENTS; CARRIER PROTEINS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; JAPAN; LIVER CIRRHOSIS; MALE; MIDDLE AGED; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RECURRENCE; RIBAVIRIN; SIMEPREVIR; TREATMENT FAILURE; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84945452043     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12427     Document Type: Article

References (32)

1. El-Serag HB,. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 1264-1273.
2. Mohd Hanafiah K, Groeger J, Flaxman AD, et al,. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333-1342.
3. Morgan TR, Ghany MG, Kim HY, et al,. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010; 52: 833-844.
4. Ogawa E, Furusyo N, Kajiwara E, et al,. Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study. J Hepatol 2013; 58: 495-501.
5. Karino T, Ozeki I, Hige S, et al,. Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C. J Viral Hepat 2014; 21: 341-347.
6. Ogawa E, Furusyo N, Nakamuta M, et al,. Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy. J Hepatol 2013; 59: 667-674.
7. Kumada H, Toyota J, Okanoue T, et al,. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 2012; 56: 78-84.
8. Ogawa E, Furusyo N, Nakamuta M, et al,. Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study. Aliment Pharmacol Ther 2013; 38: 1076-1085.
9. Jacobson IM, Dore GJ, Foster GR, et al,. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014; 384: 403-413.
10. Manns M, Marcellin P, Poordad F, et al,. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014; 384: 414-426.
11. Zeuzem S, Berg T, Gane E, et al,. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology 2014; 146: 430-441.
12. Fried MW, Buti M, Dore GJ, et al,. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 2013; 58: 1918-1929.
13. Forns X, Lawitz E, Zeuzem S, et al,. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 2014; 146: 1669-1679.
14. Hayashi N, Izumi N, Kumada H, et al,. Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. J Hepatol 2014; 61: 219-227.
15. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20: 15-20.
16. Sterling RK, Lissen E, Clumeck N, et al,. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-1325.
17. Vallet-Pichard A, Mallet V, Nalpas B, et al,. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 2007; 46: 32-36.
18. Tanaka Y, Nishida N, Sugiyama M, et al,. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
19. Ochi H, Maekawa T, Abe H, et al,. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy-a genome-wide study of Japanese HCV virus patients. Gastroenterology 2010; 139: 1190-1197.
20. Suzuki F, Sezaki H, Akuta N, et al,. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. J Clin Virol 2012; 54: 352-354.
21. Romano KP, Ali A, Royer WE, et al,. Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding. Proc Natl Acad Sci U S A 2010; 107: 20986-20991.
22. Poveda E, Wyles DL, Mena A, et al,. Update on hepatitis C virus resistance to direct-acting antiviral agents. Antiviral Res 2014; 108: 181-191.
23. American Association for the Study of Liver Disease (AASLD). Practice guidelines: Recommendations for Testing, Managing, and Treating Hepatitis C. Available at: http://www.hcvguidelines.org/full-report/retreatment-persons-whom-prior-therapy-has-failed (accessed 20 January 2015).
24. Sullivan JC, De Meyer S, Bartels DJ, et al,. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis 2013; 57: 221-229.
25. Furusyo N, Ogawa E, Nakamuta M, et al,. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. J Hepatol 2013; 59: 205-212.
26. Shimada N, Toyoda H, Tsubota A, et al,. Baseline factors and very early viral response (week 1) for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study. J Gastroenterol 2014; 49: 1485-1494.
27. Tsubota A, Shimada N, Atsukawa M, et al,. Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with hepatitis C virus genotype 1b. J Gastroenterol Hepatol 2014; 29: 144-150.
28. Reddy KR, Zeuzem S, Zoulim F, et al,. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial. Lancet Infect Dis 2015; 15: 27-35.
29. Sezaki H, Suzuki F, Hosaka T, et al,. Effectiveness and safety of reduced-dose telaprevir-based triple therapy in chronic hepatitis C patients. Hepatol Res 2014; 44: E163-E171.
30. Kawakami Y, Suzuki F, Karino Y, et al,. Telaprevir is effective given every 12 h at 750 mg with pegylated interferon-α2b and ribavirin to Japanese patients with HCV-1b IL28B rs8099917 TT. Antivir Ther 2014; 19: 277-285.
31. Oze T, Hiramatsu N, Yakushijin T, et al,. The prospective randomized study on telaprevir at 1500 or 2250 mg with pegylated interferon plus ribavirin in Japanese patients with HCV genotype 1. J Gastroenterol 2015; 50: 313-322.
32. Furusyo N, Ogawa E, Murata M, et al,. Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response. J Antimicrob Chemother 2014; 69: 483-490.